Primary immunodeficiency diseases
Drug research and approvals for primary immunodeficiency diseases: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 78 studies of primary immunodeficiency diseases are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 78
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 2
Recruiting Now
Newest start dates first, of 78 recruiting on ClinicalTrials.gov ↗- A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South KoreaNCT07445087 · Not reported · Takeda · starts Sep 21, 2026
- Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With…NCT07654829 · Phase 4 · KalVista Pharmaceuticals, Ltd. · starts Aug 17, 2026
- Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)NCT07215416 · Phase 1 / Phase 2 · Timothy Yu · starts Aug 1, 2026
- Exercise Intervention and ImmunodeficiencyNCT07698197 · Not applicable · Yale University · starts Jul 17, 2026
- Primitive Immunodeficiency, Intrauterine Devices and Menstrual Hygiene ProductsNCT06519734 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Jun 1, 2026
- A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary AngioedemaNCT07293364 · Not applicable · Takeda · starts May 12, 2026
- Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune…NCT07284641 · Phase 2 · Paul Szabolcs · starts May 4, 2026
- Donidalorsen Treatment in Children With Hereditary AngioedemaNCT07298447 · Phase 3 · Ionis Pharmaceuticals, Inc. · starts Apr 21, 2026
- Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)NCT07428499 · Phase 3 · ADARx Pharmaceuticals, Inc. · starts Apr 2, 2026
- Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdemaNCT07448181 · Not reported · Istituti Clinici Scientifici Maugeri SpA · starts Feb 23, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Apr 10, 2024 | Phase Ib open label basket trial of ray121 to inhibit classical complement pathway in immunological diseases (rainbow trial)RAY121 | Chugai Pharmaceutical | Ongoing |
| Apr 3, 2019 | "a phase III, open-label, prospective, multicenter study to assess efficacy, safety and pharmacokinetics of kedrion intravenous immunoglobulin (ivig) 10% in…HUMAN IMMUNOGLOBULIN, 10% SOLUTION | KEDRION S.P.A. | Closed |
| Oct 30, 2017 | Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (octanorm) in patients with primary…OCTANORM 16.5% | OCTAPHARMA CANADA INC | Ongoing |
| Oct 23, 2015 | An open-label, multi-center study to evaluate the safety and pharmacokinetics of igsc 20% administered for 6 months in subjects with primary immunodeficiencyIGSC 20%, IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN), 20% CAPRYLATE/CHROMATOGRAPHY… | Grifols | Ongoing |
| Oct 2, 2014 | Clinical phase III study to evaluate the pharmacokinetics, efficacy, tolerability and safety of subcutaneous human immunoglobulin (octanorm 16.5%) in patients…OCTANORM 16.5% | OCTAPHARMA CANADA INC | Ongoing |
| Dec 12, 2013 | Reducing-intensity conditioning for children and adults with hemophagocytic syndromes or selected primary immune deficiencies (richi)FLUDARABINE / MABCAMPATH (ALEMTUZUMAB) / MELPHALAN / METHYLPREDNISOLONE /… | C17 | Ongoing |
| Jun 27, 2013 | A clinical study of immune globulin subcutaneous (human) 20% solution (igsc,20%) for the evaluation of efficacy, safety, tolerability and pharmacokinetics in…IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN), 20% SOLUTION (IGSC, 20%) | Baxter International | Pending |
Medicines Authorised in the EU
Newest first| May 21, 2026 | Joenjaleniolisib · orphan | Pharming Technologies B.V. | EMA ↗ |
| Apr 27, 2026 | Xolremdimavorixafor · orphan | Norgine B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA